PETCM
CAS: 10129-56-3
Ref. 3D-KAA12956
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 2500mg | Discontinued |
Product Information
- Petcm
- Apoptosis Activator I
- 1-(4-Pyridyl)-2-Hydroxy-3,3,3-Trichloropropane
- 1,1,1-Trichloro-3-(4-Pyridyl)Propan-2-Ol
- a-(Trichloromethyl)-4-pyridineethanol
- α-(Trichloromethyl)-4-pyridineethanol, 1-(4-Pyridyl)-2-hydroxy-3,3,3-trichloropropane
- 1,1,1-Trichloro-3-(Pyridin-4-Yl)Propan-2-Ol
- (2S)-1,1,1-trichloro-3-(pyridin-4-yl)propan-2-ol
- (2R)-1,1,1-trichloro-3-(pyridin-4-yl)propan-2-ol
PETCM is a fragment of the epidermal growth factor (EGF) that binds to the EGF receptor and activates it. PETCM has been shown to stimulate cell proliferation and inhibit apoptosis in vitro. It also binds to calmodulin, a calcium-binding protein, and may have biological effects on cells through this binding. PETCM has been studied in clinical trials for its potential use as a therapeutic agent in urothelial carcinoma. In these studies, PETCM was found to be well tolerated and showed some evidence of efficacy against this type of cancer.
PETCM may have potential as a drug target for cyclic nucleotide phosphodiesterase (PDE) inhibitors, which are used to treat disorders such as Parkinson’s disease and epilepsy. Structural analysis shows that PETCM may bind competitively with PDEs at the same site as cAMP. This binding prevents the hydrolysis of cAMP into AMP, which would activate downstream enzymes
